These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 21292168)

  • 1. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
    Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
    J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
    Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
    Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.
    Paulson DM; Kennedy DT; Donovick RA; Carpenter RL; Cherubini M; Techner L; Du W; Ma Y; Schmidt WK; Wallin B; Jackson D
    J Pain; 2005 Mar; 6(3):184-92. PubMed ID: 15772912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection.
    Wolff BG; Weese JL; Ludwig KA; Delaney CP; Stamos MJ; Michelassi F; Du W; Techner L
    J Am Coll Surg; 2007 Apr; 204(4):609-16. PubMed ID: 17382220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway.
    Ludwig K; Enker WE; Delaney CP; Wolff BG; Du W; Fort JG; Cherubini M; Cucinotta J; Techner L
    Arch Surg; 2008 Nov; 143(11):1098-105. PubMed ID: 19015469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery.
    Delaney CP; Weese JL; Hyman NH; Bauer J; Techner L; Gabriel K; Du W; Schmidt WK; Wallin BA;
    Dis Colon Rectum; 2005 Jun; 48(6):1114-25; discussion 1125-6; author reply 1127-9. PubMed ID: 15906123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
    Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
    Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
    Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label uses of alvimopan and methylnaltrexone.
    Rodriguez RW
    Am J Health Syst Pharm; 2014 Sep; 71(17):1450-5. PubMed ID: 25147168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Webster LR; Yamada T; Arjona Ferreira JC
    Pain Med; 2017 Dec; 18(12):2350-2360. PubMed ID: 28371937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study.
    Viscusi ER; Goldstein S; Witkowski T; Andonakakis A; Jan R; Gabriel K; Du W; Techner L; Wallin B
    Surg Endosc; 2006 Jan; 20(1):64-70. PubMed ID: 16333556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.
    Herzog TJ; Coleman RL; Guerrieri JP; Gabriel K; Du W; Techner L; Fort JG; Wallin B
    Am J Obstet Gynecol; 2006 Aug; 195(2):445-53. PubMed ID: 16626607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.
    Michna E; Blonsky ER; Schulman S; Tzanis E; Manley A; Zhang H; Iyer S; Randazzo B
    J Pain; 2011 May; 12(5):554-62. PubMed ID: 21429809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Alvimopan on Return of Bowel Function After Major Spine Surgery - A Prospective, Randomized, Double-Blind Study.
    Dunn LK; Thiele RH; Lin MC; Nemergut EC; Durieux ME; Tsang S; Shaffrey ME; Smith JS; Shaffrey CI; Naik BI
    Neurosurgery; 2019 Aug; 85(2):E233-E239. PubMed ID: 30951602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
    Lee CT; Chang SS; Kamat AM; Amiel G; Beard TL; Fergany A; Karnes RJ; Kurz A; Menon V; Sexton WJ; Slaton JW; Svatek RS; Wilson SS; Techner L; Bihrle R; Steinberg GD; Koch M
    Eur Urol; 2014 Aug; 66(2):265-72. PubMed ID: 24630419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.
    Rauck R; Slatkin NE; Stambler N; Harper JR; Israel RJ
    Pain Pract; 2017 Jul; 17(6):820-828. PubMed ID: 27860208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus.
    Wolff BG; Michelassi F; Gerkin TM; Techner L; Gabriel K; Du W; Wallin BA;
    Ann Surg; 2004 Oct; 240(4):728-34; discussion 734-5. PubMed ID: 15383800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
    Jamal MM; Adams AB; Jansen JP; Webster LR
    Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.